Track topics on Twitter Track topics that are important to you
A collaboration between Integrated BioTherapeutics (IBT) and The Scripps Research Institute (TSRI) has been awarded a $6.6 million, 5-year grant by the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to develop a vaccine that protects against all ebolaviruses. "This award will enable us to address a pressing global public health need, namely a single vaccine that can protect against all ebolaviruses,” stated IBT’s CSO, Dr. M. Javad Aman, who is co-principal investigator for the collaboration. “To meet this challenge, we have assembled a unique team of experts in immunogen design, structural biology, vaccine development and animal models of filovirus infection.” Filoviruses including Ebola, Sudan, Bundibugyo and Marburg cause hemorrhagic fever in humans, and infection is lethal in 40-90% of cases. The most recent Ebola virus outbreak in West Africa was caused by the Zaire Ebolavirus (EBOV), and led to 29,000 infections ...
Original Article: IBT, Scripps Win $6.6M to Develop Pan-Ebolavirus VaccineNEXT ARTICLE
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...